JFG
RLAY icon

Jefferies Financial Group’s Relay Therapeutics RLAY Stock Holding History

Jefferies Financial Group’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-14,500
Closed -$239K – 1952
2023
Q1 		$239K Buy
+14,500
New +$260K ﹤0.01% 1302

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Jefferies Financial Group's RLAY Position: Q2 2024 in Review

Jefferies Financial Group sold out of Relay Therapeutics (RLAY) in Q2 2024, closing a stake of 101,563 shares — an estimated $843K sold.

Jefferies Financial Group first reported a position in RLAY in Q1 2023 and held it in 5 quarters. The position peaked at $5.45M in Q2 2023. 178 funds tracked by Wall St. Rank hold RLAY as of Q2 2024.

  • Jefferies Financial Group reported no remaining Relay Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Jefferies Financial Group sold 101,563 Relay Therapeutics shares in Q2 2024, an estimated $843K.
  • Jefferies Financial Group first reported a position in Relay Therapeutics in Q1 2023 and held it in 5 quarters.
  • Jefferies Financial Group's Relay Therapeutics position peaked at $5.45M in Q2 2023.
  • 178 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2024.

Based on Jefferies Financial Group's 13F filing for Q2 2024, filed 13 Aug 2024.